Cargando…
Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients
BACKGROUND & AIMS: Liver transplant recipients (LTRs) show a decreased immune response after 2 severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccinations compared with healthy controls (HCs). Here, we investigated the immunogenicity of additional vaccinations. METHODS: In thi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the AGA Institute
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287575/ https://www.ncbi.nlm.nih.gov/pubmed/35850415 http://dx.doi.org/10.1016/j.cgh.2022.06.028 |
_version_ | 1784748281403801600 |
---|---|
author | Harberts, Aenne Schaub, Golda M. Ruether, Darius F. Duengelhoef, Paul M. Brehm, Thomas T. Karsten, Hendrik Fathi, Anahita Jahnke-Triankowski, Jacqueline Fischer, Lutz Addo, Marylyn M. Haag, Friedrich Luetgehetmann, Marc Lohse, Ansgar W. Schulze zur Wiesch, Julian Sterneck, Martina |
author_facet | Harberts, Aenne Schaub, Golda M. Ruether, Darius F. Duengelhoef, Paul M. Brehm, Thomas T. Karsten, Hendrik Fathi, Anahita Jahnke-Triankowski, Jacqueline Fischer, Lutz Addo, Marylyn M. Haag, Friedrich Luetgehetmann, Marc Lohse, Ansgar W. Schulze zur Wiesch, Julian Sterneck, Martina |
author_sort | Harberts, Aenne |
collection | PubMed |
description | BACKGROUND & AIMS: Liver transplant recipients (LTRs) show a decreased immune response after 2 severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccinations compared with healthy controls (HCs). Here, we investigated the immunogenicity of additional vaccinations. METHODS: In this prospective study, humoral (anti-SARS-CoV-2 receptor-binding domain [anti-S RBD]) and cellular (interferon-gamma release assay) immune responses were determined after mRNA-based SARS-CoV-2 vaccination in 106 LTRs after a third vaccination and in 36 LTRs after a fourth vaccination. Patients with anti-S RBD antibody levels >0.8 arbitrary unit (AU)/mL after vaccination were defined as responders. RESULTS: After 3 vaccinations, 92% (97/106) of LTRs compared with 100% (28/28) of HCs were responders. However, the antibody titer of LTRs was lower compared with HCs (1891.0 vs 21,857.0 AU/mL; P < .001). Between a second and third vaccination (n = 75), the median antibody level increased 67-fold in LTRs. In patients seronegative after 2 vaccinations, a third dose induced seroconversion in 76% (19/25), whereas all HCs were already seropositive after 2 vaccinations. A spike-specific T-cell response was detected in 72% (28/39) after a third vaccination compared with 32% (11/34) after a second vaccination. Independent risk factors for a low antibody response (anti-S RBD <100 AU/mL) were first vaccination within the first year after liver transplant (odds ratio [OR], 8.00; P = .023), estimated glomular filtration rate <45 mL/min (OR, 4.72; P = .006), and low lymphocyte counts (OR, 5.02; P = .008). A fourth vaccination induced a 9-fold increase in the median antibody level and seroconversion in 60% (3/5) of previous non-responders. CONCLUSIONS: A third and fourth SARS-CoV-2 vaccination effectively increases the humoral and cellular immune response of LTRs, but to a lesser extent than in HCs. A fourth vaccination should be generally considered in LTRs. |
format | Online Article Text |
id | pubmed-9287575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | by the AGA Institute |
record_format | MEDLINE/PubMed |
spelling | pubmed-92875752022-07-18 Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients Harberts, Aenne Schaub, Golda M. Ruether, Darius F. Duengelhoef, Paul M. Brehm, Thomas T. Karsten, Hendrik Fathi, Anahita Jahnke-Triankowski, Jacqueline Fischer, Lutz Addo, Marylyn M. Haag, Friedrich Luetgehetmann, Marc Lohse, Ansgar W. Schulze zur Wiesch, Julian Sterneck, Martina Clin Gastroenterol Hepatol Original Article BACKGROUND & AIMS: Liver transplant recipients (LTRs) show a decreased immune response after 2 severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccinations compared with healthy controls (HCs). Here, we investigated the immunogenicity of additional vaccinations. METHODS: In this prospective study, humoral (anti-SARS-CoV-2 receptor-binding domain [anti-S RBD]) and cellular (interferon-gamma release assay) immune responses were determined after mRNA-based SARS-CoV-2 vaccination in 106 LTRs after a third vaccination and in 36 LTRs after a fourth vaccination. Patients with anti-S RBD antibody levels >0.8 arbitrary unit (AU)/mL after vaccination were defined as responders. RESULTS: After 3 vaccinations, 92% (97/106) of LTRs compared with 100% (28/28) of HCs were responders. However, the antibody titer of LTRs was lower compared with HCs (1891.0 vs 21,857.0 AU/mL; P < .001). Between a second and third vaccination (n = 75), the median antibody level increased 67-fold in LTRs. In patients seronegative after 2 vaccinations, a third dose induced seroconversion in 76% (19/25), whereas all HCs were already seropositive after 2 vaccinations. A spike-specific T-cell response was detected in 72% (28/39) after a third vaccination compared with 32% (11/34) after a second vaccination. Independent risk factors for a low antibody response (anti-S RBD <100 AU/mL) were first vaccination within the first year after liver transplant (odds ratio [OR], 8.00; P = .023), estimated glomular filtration rate <45 mL/min (OR, 4.72; P = .006), and low lymphocyte counts (OR, 5.02; P = .008). A fourth vaccination induced a 9-fold increase in the median antibody level and seroconversion in 60% (3/5) of previous non-responders. CONCLUSIONS: A third and fourth SARS-CoV-2 vaccination effectively increases the humoral and cellular immune response of LTRs, but to a lesser extent than in HCs. A fourth vaccination should be generally considered in LTRs. by the AGA Institute 2022-11 2022-07-16 /pmc/articles/PMC9287575/ /pubmed/35850415 http://dx.doi.org/10.1016/j.cgh.2022.06.028 Text en © 2022 by the AGA Institute. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Harberts, Aenne Schaub, Golda M. Ruether, Darius F. Duengelhoef, Paul M. Brehm, Thomas T. Karsten, Hendrik Fathi, Anahita Jahnke-Triankowski, Jacqueline Fischer, Lutz Addo, Marylyn M. Haag, Friedrich Luetgehetmann, Marc Lohse, Ansgar W. Schulze zur Wiesch, Julian Sterneck, Martina Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients |
title | Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients |
title_full | Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients |
title_fullStr | Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients |
title_full_unstemmed | Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients |
title_short | Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients |
title_sort | humoral and cellular immune response after third and fourth sars-cov-2 mrna vaccination in liver transplant recipients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287575/ https://www.ncbi.nlm.nih.gov/pubmed/35850415 http://dx.doi.org/10.1016/j.cgh.2022.06.028 |
work_keys_str_mv | AT harbertsaenne humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT schaubgoldam humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT ruetherdariusf humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT duengelhoefpaulm humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT brehmthomast humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT karstenhendrik humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT fathianahita humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT jahnketriankowskijacqueline humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT fischerlutz humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT addomarylynm humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT haagfriedrich humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT luetgehetmannmarc humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT lohseansgarw humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT schulzezurwieschjulian humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients AT sterneckmartina humoralandcellularimmuneresponseafterthirdandfourthsarscov2mrnavaccinationinlivertransplantrecipients |